Emerging studies have shown the up-regulated levels of MYC protein as a downstream effector of frequently altered kinase MAPK and RAS pathways in CRC, contributing to primary and secondary resistance in targeted therapy.32 This evidence concerns the gene MYC and colorectal carcinoma.